Finished Dosage Form

Convenience and Patient Compliance
Opting for finished dosage form forms offers a multitude of benefits for pharmaceutical companies looking to balance efficiency and cost-effectiveness. finished dosage forms, such as tablets and capsules, allow for improved patient compliance as they offer convenient administration, allowing patients to take their medication without the need for healthcare professional involvement. This convenience leads to more effective treatment outcomes and improved patient satisfaction.

Accurate Dosing and Uniform Drug Content
Finished dosage forms allow for precise dosing, and ensure the accurate delivery of the prescribed amount of medication. They provide uniform drug content, minimizing variations in dosage and enhancing consistency in drug administration.

Stability and Shelf Life
Another advantage of finished dosage forms is their extended shelf life and stability. Compared to liquid or semisolid formulations, finished dosage forms are generally more stable and have a longer shelf life. They can retain potency over time and are less susceptible to degradation or contamination when stored correctly. This stability ensures that the medication remains effective throughout its intended shelf life, making OSD a reliable solution for pharmaceutical companies looking to meet the demands of global supply chains while maintaining product quality and ensuring patient safety.

Clinical Development and Control Processes
Choosing finished dosage forms also offers competitive advantages to pharmaceutical companies in terms of clinical development, production cost, and control processes. finished dosage forms allow for easier clinical development as they are simple to manufacture and can be easily scaled up. Moreover, finished dosage forms can be produced at a lower cost than other drug formulation types, as they require less equipment and fewer processing steps. Additionally, finished dosage forms offer better control processes, as they can be easily analyzed and tested to ensure product specifications are met, leading to more consistent and reliable product quality.

The manufacture of finished dosage forms continues to evolve, with key drivers including functional improvements, safety and overall cost of development and commercial manufacture.

As plant network strategies evolve and new products progress there has been more alignment between development and commercial for manufacturing process streamlining and improved quality. While wet granulation remains required and preferred in some situations, this has resulted in more emphasis on direct blend and dry granulation processing for tablets and capsule manufacturing. This in turn has put more emphasis on raw material and process control.

From a regulatory perspective, Quality by Design (QbD) and Process Analytical Technology (PAT) principles are increasingly being sought, and beyond this continuous manufacturing, particularly for finished dosage forms, has emerged as one of the rising star technologies.

The major trend towards continuous processing where multiple continuous unit operations are coupled into an integrated system has occurred using joint industry, academia and process equipment supplier collaborations; and the genre includes the primary processes in oral finished dosage form manufacture direct blend, dry and wet granulation, tableting/encapsulation and tablet film coating. Drivers include streamlined development, lower and more flexible manufacturing, higher quality product and lower net costs.

Life cycle management strategies such as fixed dose combinations, extended release and pediatric forms continue to increase in demand. Combining new chemical entities with an existing drug to explore new clinical benefits and newer indications is on the rise. New chemical entities coming out of discovery continue to have poor solubility and bioavailability challenges, and the industry continues to invest in ways and means to deliver the drug with a better clinical outcome. Contract developers continue to support the industry in solving these challenges.

Increasingly the finished dosage formsector, which traditionally focused on development and manufacture, is overlapping with other sectors involved in electronic data transfer and management and supply chain logistics as they look for areas of expansion in non-traditional sectors, particularly as the sector looks for a more efficient and integrated supply chain. Indeed, the longer term trend is towards integration throughout the supply chain with companies offering API manufacture all the way through to finished drug manufacture and packaging. As a result, much of the expertise that is traditionally in pharma is now residing within the finished dosage form sector and this is undoubtedly changing the relationship between client and customer with even risk sharing models becoming more common. 

Ensure Product Quality & Safety
A finished dosage form company's primary goal is to make medication that works. However, if a sound finished dosage form quality assurance system is not in place, the finished dosage form products that are intended to save lives can instead cause irreversible harm or even death. The finished dosage form industry, and every employee involved in finished dosage form quality assurance, should always maintain focus on the people taking the medications and the potential impact on their health.

Avoid Negative Publicity
A robust finished dosage form quality assurance system ensures that products are effective and safe. Following good manufacturing practices (GMP) and enacting comprehensive inspection policies help drug manufacturers produce the highest quality products and avoid reputation-damaging incidents. Pharma quality assurance protects against negative publicity.

Improve Efficiency
Finished dosage form quality assurance is primarily about producing reliable and safe products. The second aspect of pharma quality assurance is that it promotes continuous improvement, from technology transfer to product development. Advanced technologies allow for tighter controls and closer monitoring of the finished dosage form manufacturing process. Automation and virtual processes increase productivity and safety, but product quality must never be compromised.

Guarantee Compliance
Regulations are constantly changing, so keeping up-to-date with pharma industry standards requires an effective finished dosage form quality assurance system that includes solid processes and risk management procedures to address regulatory compliance. Many compliance issues that the finished dosage form industry faces are not due to intentional wrongdoing. Instead, these costly errors can most often be attributed to poor workflows, human error or sloppy record-keeping.

Texture, mouthfeel, and coating
Surface texture was the second most commonly reported cause (relating to the dosage form) of swallowing difficulties in people with dysphagia, with 70.5% of participants identifying a problem with this feature. Surface characteristics further contributed to 18.5% of use difficulties in older people. Participants used the term “chalky” to describe the texture of tablets that were difficult to take. “Chalkiness” was also a variable that was directly measured to assess the acceptability of chewable formulations using the visual analog scale, and the results indicate an overall preference toward “not chalky at all” chewable formulations.

Taste
Taste was significant in predicting the acceptability of an alendronic acid tablet formulation using the Medicine Acceptability Questionnaire. Some active pharmaceutical ingredients, such as ferrous fumarate, have an inherently bitter taste and require taste masking with food. The need for taste masking increased when medications were crushed; various substances such as milk, apple juice, bread, tea, and fruit smoothies were used to mask the “horrible” taste. Further studies found that in 19% (205) of 1079 evaluations, older people used food or drink just before or after administration to mask the taste or to improve ease of swallowing.

Appearance
Difficulties distinguishing between different strengths because of similarities in appearance led to discomfort and clinical deterioration, although sometimes additional markings such as embossments could help patients differentiate tablets. Smaller tablets, including mini tablets, were difficult to see, especially for older people with visual impairments. Conversely, large tablets can lead to a psychological block and anxiety before taking medication. The type of dosage affected older people's views on appearance. Concerns were raised in relation to the appearance of granules, which were considered the least acceptable “alternative dosage form” alongside chewable tablets in older people. Furthermore, when comparing tablet and liquid formulations of alendronic acid, there was a general trend for the liquid to perform better in terms of appearance, although this difference was not statistically significant.

National New High-tech Enterprise
Key New High-tech Enterprise of National Torch Plan
National superior enterprise of intellectual property
Provincial New High-tech Research & Development Center
Zhejiang Provincial Enterprise Technology Center
Zhejiang Famous Trademark
Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute
Zhejiang province per mu benefit leading enterprises
Gene-engineering New Drug R&D Technology and Service Sub-platform
Provincial Post-doctoral Scientific Research Working Center
Excellent industrial products in Zhejiang Province
Hangzhou Academician Expert Working Center
Hangzhou Top Ten New High-tech Enterprise
Zhejiang Green Enterprise